# US 2018/0023056 A1 · Reprogramming Method for Producing Induced Pluripotent Stem Cells (iPSC)

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0023056 A1
- Document ID: US20180023056A1
- Status: Published application
- Kind: A1
- Application number: 15/547,212
- Filed: 2016-02-01
- Published: 2018-01-25
- Earliest claimed: 2015-01-30
- Assignees: Centre National de la Recherche Scientifique (CNRS)
- Applicants: Centre National de la Recherche Scientifique (CNRS
- Inventors: Pierre Roux
- Web page: https://patentgrep.com/patent/US20180023056A1

## CPC

- C12N 5/0696: {Artificially induced pluripotent stem cells, e.g. iPS}
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 35/00: Antineoplastic agents
- C12N 2501/40: Regulators of development
- C12N 2501/998: Proteins not provided for elsewhere
- C12N 2506/1307: from adult fibroblasts
- C12N 2510/00: Genetically modified cells
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention is in the field of stem cells. Particularly, the present invention relates to a reprogramming method for producing induced pluripotent stem cells (iPSC) by transducing somatic differentiated cells with a viral vector expressing Δ133p53β isoform, Δ133p53γ isoform or both Δ133p53β and Δ133p53γ isoforms; to induced pluripotent stem cells as produced by this method; to uses thereof in cell therapy and as an in vitro model for studying various diseases; and to a method for detecting iPSC.

## Claims

### Claim 1

A reprogramming method for producing induced pluripotent stem cells (iPSC), comprising:
a) transducing somatic differentiated cells with a vector expressing Δ133p53β isoform, Δ133p53γ isoform or both Δ133p53β and Δ133p53γ isoforms;
b) culturing transduced somatic differentiated cells in a medium supporting their expansion; and
c) isolating induced pluripotent stem cells.

### Claim 2 (depends on 1)

The method according to claim 1, wherein somatic differentiated cells are selected from the group comprising peripheral blood mononuclear cells (PBMC), fibroblasts and CD4+ lymphocytes, said cells being preferably selected from fibroblasts.

### Claim 3 (depends on 1, 2)

The method according to claim 1 or claim 2, wherein the vector expressing Δ133p53β isoform, Δ133p53γ isoform or both Δ133p53β and Δ133p53γ isoforms is a retroviral vector, preferably a Murine Stem Cell Virus (MSCV) vector, comprising a nucleic acid molecule encoding Δ133p53β isoform, Δ133p53γ isoform or both Δ133p53β and Δ133p53γ isoforms and elements necessary to allow expression thereof.

### Claim 4 (depends on 1, 2, 3)

The method according to anyone of claims 1 to 3, wherein the medium of step b) is a basal medium comprising inorganic salts, amino acids, vitamins and glucose, β-mercaptoethanol, at least one antibiotic, and bFGF.

### Claim 5 (depends on 1, 2, 3, 4)

The method according to anyone of claims 1 to 4, wherein the induced pluripotent stem cells (iPSC) are isolated by means selected from the group comprising a selection based on stem cells surface markers, a flow cytometry based on side-population (SP) phenotype by DNA dye exclusion, an embryoid formation and iPSC colony picking.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The method according to anyone of claims 1 to 5, further comprising step al) of culturing the somatic dedifferentiated cells before the step a) of transducing said cells.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The method according to any one of claims 1 to 6, wherein the somatic differentiated cells are transduced with vector expressing Δ33p53β isoform.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

Induced pluripotent stem cells (iPSC) obtained from the reprogramming method as claimed in any one of claims 1 to 7.

### Claim 9 (depends on 8)

Induced pluripotent stem cells (iPSC) of claim 8 for use in cell therapy.

### Claim 10 (depends on 8, 9)

Induced pluripotent stem cells (iPSC) of claim 8 or 9 for use as therapeutic agent in the treatment of aging-associated and/or degenerative diseases.

### Claim 11 (depends on 10)

Induced pluripotent stem cells (iPSC) of claim 10, wherein aging-associated et degenerative diseases are selected from the group comprising cardiovascular diseases, diabetes, cancer, arthritis, hypertension, myocardial infection, strokes, amyotrophic lateral sclerosis, Alzheimer's disease and Parkinson disease.

### Claim 12 (depends on 8)

Use of the induced pluripotent stem cells (iPSC) of claim 8 in vitro as model for study diseases selected from the group comprising amyotrophic lateral sclerosis, adenosine deaminase deficiency-related severe combined immunodeficiency, Shwachman-Bodian-Diamond syndrome, Gaucher disease type III, Duchene and Becker muscular dystrophies, Parkinson's disease, Huntington's disease, type 1 diabetes mellitus, Down syndrome and spinal muscular atrophy.

### Claim 13

An in vitro method for detecting Induced pluripotent stem cells (iPSC) comprising detecting the presence of Δ133p53β isoform, Δ133p53γ isoform or both Δ133p53β and Δ133p53γ isoforms by detecting Δ133p53β isoform, Δ133p53γ isoform or both Δ133p53β and Δ133p53γ isoforms polypeptide and/or by detecting Δ133p53β isoform, Δ133p53γ isoform or both Δ133p53β and Δ133p53γ isoforms mRNA and/or a fragment thereof.

### Claim 14 (depends on 13)

The in vitro method of claim 13, wherein the detecting is based on detecting the presence of Δ133p53β isoform by detecting Δ133p53β isoform polypeptide and/or a fragment thereof, and/or by detecting Δ133p53β isoform mRNA and/or a fragment thereof.
